MedTrace Logo

UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes

NCT06751199 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-12-27

No results posted yet for this study

Summary

The aim is to Investigate the safety and efficacy of Portal vein infusion Allogeneic Human umbilical cord mesenchymal stem cells combined with Allogeneic islet transplantation for the treatment of diabetes

Conditions

Interventions

DRUG

human umbilical cord mesenchymal stem cells

Portal vein infusion human umbilical cord mesenchymal stem cells

DRUG

allogeneic islet

Portal vein infusion of allogeneic islet

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    lead OTHER

Principal Investigators

  • Hao Yin · Shanghai Changzheng Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2026-07-30
Completion
2026-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06751199 on ClinicalTrials.gov